Last CNY24.72 CNY
Change Today +0.12 / 0.49%
Volume 4.3M
002437 On Other Exchanges
Symbol
Exchange
Shenzhen
As of 3:00 AM 10/24/14 All times are local (Market data is delayed by at least 15 minutes).

harbin gloria pharmaceutic-a (002437) Snapshot

Open
CNY24.70
Previous Close
CNY24.60
Day High
CNY24.92
Day Low
CNY24.45
52 Week High
10/16/14 - CNY26.99
52 Week Low
10/28/13 - CNY13.12
Market Cap
17.3B
Average Volume 10 Days
9.7M
EPS TTM
CNY0.56
Shares Outstanding
700.0M
EX-Date
07/4/14
P/E TM
44.1x
Dividend
CNY0.04
Dividend Yield
0.16%
Current Stock Chart for HARBIN GLORIA PHARMACEUTIC-A (002437)

Related News

No related news articles were found.

harbin gloria pharmaceutic-a (002437) Related Businessweek News

No Related Businessweek News Found

harbin gloria pharmaceutic-a (002437) Details

Harbin Gloria Pharmaceuticals Co., Ltd. is engaged in the research, development, production, and sale of pharmaceutical products primarily in the People’s Republic of China. The company offers orthopedic medicines, antineoplastics, nutrition products, rheumatology drugs, digestive and respiratory system medicines, cardiovascular medicines, liver disease medications, gynecology medications, and antibiotics. It also provides circulatory system, pediatrics, uropoiesis and reproduction, immune regulation, and other products. Harbin Gloria Pharmaceuticals Co., Ltd. was founded in 2000 and is based in Harbin, the People’s Republic of China.

Founded in 2000

harbin gloria pharmaceutic-a (002437) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

harbin gloria pharmaceutic-a (002437) Key Developments

Harbin Gloria Pharmaceuticals Co., Ltd to Report Q3, 2014 Results on Oct 25, 2014

Harbin Gloria Pharmaceuticals Co., Ltd announced that they will report Q3, 2014 results on Oct 25, 2014

Harbin Gloria Pharmaceuticals Co., Ltd, Special/Extraordinary Shareholders Meeting, Oct 24, 2014

Harbin Gloria Pharmaceuticals Co., Ltd, Special/Extraordinary Shareholders Meeting, Oct 24, 2014., at 14:00 China Standard Time. Agenda: To consider the restricted stock incentive plan (draft revision) and its summary; to consider implementation and appraisal management measures on the restricted stock incentive plan; to identify de facto controller Zhu Jiman as plan participant; to identify Wang Dongxu, the shareholder with above 5% shares, as plan participant; to identify Zhu Ji'an, immediate relatives of the de facto controller Zhu Jiman, as plan participant; and to mandate to the board to handle matters in relation to the restricted stock incentive plan.

Harbin Gloria Pharmaceuticals Co., Ltd Announces Election of Non-Independent and Independent Directors

Harbin Gloria Pharmaceuticals Co. Ltd. announced that the 2nd extraordinary general meeting held on 09 September 2014, approved the election of Zhu Jiman, Wang Dongxu, Yang Hongbing, Guo Leifeng, Li Junling and Diao Xiuqiang as non-independent directors and election of Guo Yunpei, Liu, James Xiao dong and Xu Xiaoge as independent directors.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
002437:CH CNY24.72 CNY +0.12

002437 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for 002437.
View Industry Companies
 

Industry Analysis

002437

Industry Average

Valuation 002437 Industry Range
Price/Earnings 52.2x
Price/Sales 11.0x
Price/Book 6.8x
Price/Cash Flow 52.1x
TEV/Sales 10.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HARBIN GLORIA PHARMACEUTIC-A, please visit www.gloria.cc. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.